Immunohistochemical investigation of angiogenic factors in parathyroid proliferative lesions

European Journal of Endocrinology

Volumn 154, Issue 6, 2006, Pages 827-833

  Lazaris, Andreas C ^a   Tseleni Balafouta, Sofia ^a   Papathomas, Thomas ^a,b   Brousalis, Theodore ^a   Thomopoulou, Georgia ^a   Agrogiannis, George ^a   Patsouris, Efstratios S ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CYCLIN D1; ENDOGLIN; MONOCLONAL ANTIBODY; TYROSINE KINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROID CELL; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SECONDARY HYPERPARATHYROIDISM; STATISTICAL ANALYSIS; TISSUE SECTION;

ADENOMA; ANTIGENS, CD; FEMALE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PARATHYROID NEOPLASMS; RECEPTORS, CELL SURFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33745712824     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02168     Document Type: Article

References (20)

1. Farber JL & Rubin E. The endocine system: parathyroid glands. In Pathology, 3rd edn, ch. 21, pp 1179-1183. Eds R Winters, M-B Murphy, & K Monroe, Philadelphia. PA: Lippincott-Raven, 1999.
2. Fraker DL. Update on the management of parathyroid tumors. Current Opinion in Oncology 2000 12 41-48.
3. Drucke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. Journal of the American Society of Nephrology 2000 11 1141-1152.
4. Turner HE, Harris AL, Melmed S & Wass JAH. Angiogenesis in endocrine tumors. Endocrine Reviews 2003 24 600-632.
5. Duff SE, Li C, Garland JM & Kumar S. CD105 is important for angiogenesis: evidence and potential applications. Federation of American Societies for Experimental Biology Journal 2003 17 984-992.
6. Frankfurt OS & Krishan A. Identification of apoptotic cells by formamide-induced DNA denaturation in condensed chromatin. Journal of Histochemistry and Cytochemistry 2001 49 369-378.
7. Kvasnicka T, Wang W, Johansson H, Sandelin K & Grimelius L. Apoptosis and growth factors in parathyroid adenomas. Hormone and Metabolic Research 1997 29 544-548.
8. Wang W, Johansson H, Kvasnicka T, Farnebo L-O & Grimelius L. Detection of apoptotic cells and expression of Ki-67 antigen, bcl-2, p53 oncoproteins in human parathyroid adenoma. Acta Pathologica Microbiologica Scandinavica 1996 104 789-796.
9. Zhang P, Duchambon P, Gogusev J, Nabarra B, Sarfati E, Bourdeau A & Drueke TB. Apoptosis in parathyroid hyperplasia of patients with primary or secondary uremic hyperparathyroidism. Kidney International 2000 57 437-445.
10. Thomopoulou GE, Tseleni-Balafouta S, Lazaris AC, Koutselini H, Kavantzas N & Davaris PS. Immunohistochemical detection of cell cycle regulators, Fhit protein and apoptotic cells in parathyroid lesions. European Journal of Endocrinology 2003 148 81-87.
11. Fonsatti E & Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. Journal of Translational Medicine 2004 2 18-21.
12. Garcia-Torre N, Buley I, Wass JAH, Jackson DG & Turner HE. Angiogenesis and lymphangiogenesis in parathyroid proliferative lesions. Journal of Clinical Endocrinology and Metabolism 2004 89 2890-2896.
13. Yamaguchi S, Yachiku S & Morikawa M. Analysis of proliferative activity of the parathyroid glands using proliferating cell nuclear antigen in patients with hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 1997 82 2681-2688.
14. Berczi C, Bosci J, Balazs G & Lukacs G. Flow cytometric DNA analysis of benign hyperfunctioning parathyroid glands: significant difference in the S phase fraction and proliferative index between adenomas and hyperplasias. Pathology 2002 34 442-445.
15. Yu JX, Zhang XT, Liao YO, Zhang OY, Chen H, Lin M & Kumar S. Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance. World Journal of Gastroenterology 2000 9 2866-2869.
16. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K & Wada H. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clinical Cancer Research 2001 7 3410-3415.
17. Gora-Tybor J, Blonski JZ & Robak T. Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia. European Cytokine Network 2005 16 41-46.
18. Carling T. Molecular pathology of parathyroid tumors. Trends in Endocrinology and Metabolism 2001 12 53-58.
19. Tominaga Y. Mechanism of parathyroid tumourigenesis in uraemia. Nephrology Dialysis Transplantation 1999 14 63-65.
20. Tominaga Y, Tsuzuki T, Uchida K, Haba T, Otsuka S, Ichimori T, Yamada K, Numano M, Tanaka Y & Takagi H. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney International 1999 55 1375-1383.